Enrollment delay does more than move a timeline. It can consume operating capacity, create repeated pre-consent work, weaken candidate momentum, and reduce the value of activity already underway.
Not every delay begins in site operations. This article focuses on the measurable waiting time that can accumulate between inquiry, intake, preliminary prescreening, follow-up, and site handoff.
Evidence context
A 2024 Tufts CSDD analysis used 645 launched drugs and 409 clinical-trial budgets to update two frequently repeated estimates about the economics of development time.
≈ $40K/day
Estimated direct daily cost to conduct Phase II and III clinical trials.
≈ $500K/day
Estimated value of a day of delayed prescription drug or biologic sales.
These are development-level industry estimates, not estimates of the cost attributable to a specific research site, a specific enrollment delay, or Consent2Randomize-supported activity. Source: Smith, DiMasi & Getz, 2024. View the PubMed record.
Cost map
Clinical trial enrollment delays can create costs beyond a delayed enrollment milestone. Depending on the study, they may extend operating activity, consume site and coordinator capacity, generate repeated pre-consent work, weaken candidate momentum, and contribute to broader development delay. The economic impact varies by protocol, site, therapeutic area, and source of delay.
Study / sponsor level
When enrollment contributes to a longer study timeline, study activity may continue longer than planned. The financial effect depends on the protocol, phase, therapeutic area, and whether the enrollment delay changes the broader study timeline.
Site level
Intake, outreach, preliminary prescreening, documentation, scheduling coordination, and status review all require time. Unresolved records can compete with coordinators’ clinical and protocol responsibilities.
Site level
Incomplete information, missed contact, unclear ownership, and inconsistent handoffs can create repeated outreach, record review, clarification, and status checking before a candidate is ready for site review.
Candidate + site level
Long or unclear gaps between inquiry and the next defined step can make an interested candidate harder to reach or more likely to disengage. Not every disengagement is preventable, which is why disposition data matters.
Sponsor / development level
Enrollment is one contributor to clinical-development timing. When enrollment materially extends a trial, the economic effect can extend beyond site operations. That broader impact should not be attributed to a single site or workflow without evidence.
Operational contribution
Site operations are only one part of enrollment performance, but they are one part a site can observe directly. Waiting time can accumulate when ownership is unclear, contact is delayed, required information is incomplete, follow-up has no defined cadence, or the handoff standard is inconsistent.
Stage 1
Referral / inquiry
Stage 2
Initial contact
Stage 3
Intake
Stage 4
Preliminary prescreen
Stage 5
Site handoff readiness
Consent2Randomize works after a referral or patient inquiry reaches the site and before consent, supporting intake, preliminary prescreening, candidate follow-up, documentation, and structured handoff preparation. The research site retains clinical judgment, formal eligibility evaluation, screening, informed consent, protocol oversight, and randomization decisions.
Referral volume is only the start
A referral count shows activity. It does not show where time accumulated, whether records progressed consistently, or which candidates remain unresolved. Those questions require stage-level timestamps, statuses, and dispositions.
How many new inquiries received a documented first contact attempt?
How long did successful contact take?
How many records completed intake and site-approved preliminary prescreening?
Which records remain unresolved, and how old are they?
How long did records take to reach the site’s defined handoff-ready state?
Operational framework
C2R uses six friction categories to organize the operational conditions that can slow candidate progression before consent. The goal is not to label every delay as preventable, but to identify which part of the workflow deserves closer review.
Access
Can interested candidates enter the intake workflow without unnecessary friction?
Intake
Is required information captured consistently and routed to the next step?
Eligibility information
Are site-approved preliminary questions organized clearly for site review?
Capacity
Is coordinator bandwidth being consumed by work that can be standardized earlier?
Workflow
Are stage ownership, statuses, handoffs, and escalation rules defined?
Follow-up
Are outreach cadence, attempt limits, and dispositions consistent?
Enrollment diagnostic
Use the Enrollment Bottleneck Diagnostic to review where operational friction may be occurring before deciding what type of intervention makes sense.
Measurement
Sites do not need a universal industry target for every interval. They need consistent definitions, timestamps, statuses, and local baselines that reveal where waiting time is accumulating.
How long a new inquiry waits before the first documented outreach attempt.
How long it takes to reach the candidate when contact is required.
Elapsed time from usable intake information to completion of site-approved preliminary questions.
How much repeated outreach is required before the record receives a defined pre-consent status.
How long candidate records remain open without a documented next step or disposition.
Elapsed time until the site has the information required for its defined pre-consent handoff.
Use your own numbers
Industry averages cannot tell a site what its own enrollment opportunity looks like. Use the Clinical Trial Enrollment Revenue Calculator to model screening, randomization, and coordinator-capacity assumptions with your own inputs.
Evidence
The development-cost figures and broader context on enrollment variability and site burden are grounded in peer-reviewed Tufts CSDD research. C2R’s workflow analysis applies that context specifically to measurable pre-consent operations at the research-site level.
Common questions
Concise answers to questions research-site teams may need to resolve when evaluating enrollment delay.
Continue Reading
Review your workflow
If referrals are arriving but candidates are stalling before site review, we can look at intake, preliminary prescreening, follow-up, documentation, and handoff ownership to identify where operational friction may be accumulating.